omniture
logo
Search
DAEWOONG PHARMACEUTICAL
Media Room

Latest News

rss

Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test

* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage ...

2021-05-27 21:00 1499

Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis (IPF) shows promising result in early stage clinical test

* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage *...

2021-05-24 16:59 1568

Daewoong showed improved performance both sales and earnings in Q1

* OP. income exceeded 20 billion won due to successful export of Fexuprazan and sales recovery ...

2021-05-07 21:00 4658

HanAll Biopharma Reports First Quarter 2021 Financial Results

* Q1'21 sales of KRW 27.8 billion increased 26% compared to Q1'20 * Q1'21 operating profit of KR...

2021-05-06 21:00 4288

Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study

SEOUL, South Korea, Nov. 6, 2020 /PRNewswire/ -- On October 27, the bridging study results on Fexup...

2020-11-06 22:00 2646

Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide

SEOUL, South Korea, Oct. 29, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon, KRX: 06...

2020-10-29 21:00 2234

Daewoong Pharmaceutical's COVID-19 Treatment Candidate Also Highly Effective against Influenza Virus

SEOUL, South Korea, Oct. 28, 2020 /PRNewswire/ -- Daewoong Pharmaceutical, a South Korean pharmaceu...

2020-10-28 22:36 1557

Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic'

SEOUL, South Korea, Oct. 27, 2020 /PRNewswire/ -- Daewoong Pharmaceutical, a South Korean pharmaceu...

2020-10-27 21:00 1264

Daewoong Pharmaceutical's new SGLT2 inhibitor for diabetes treatment demonstrates remarkable effect in phase 2 clinical trial

SEOUL, South Korea, Sept. 29, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) (CEOSengho Je...

2020-09-29 15:00 2064

Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment

* Daewoong Pharmaceutical's enavogliflozin to demonstrate remarkable blood glucose lowering effec...

2020-09-28 20:00 1953
Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment

Daewoong Pharmaceutical Acquires Halal Certification for 'Easyef' through Daewoong Infion

SEOUL, South Korea and JAKARTA, Indonesia, May 27, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (CE...

2020-05-27 10:00 4409
Daewoong Pharmaceutical Acquires Halal Certification for 'Easyef' through Daewoong Infion

Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker

SEOUL, South Korea, May 11, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) unveiled for th...

2020-05-11 08:00 5290
Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker

Daewoong Infion obtained World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells

SEOUL, South Korea, Jan. 9, 2020 /PRNewswire/ -- Daewoong Infion Co. has achieved world's first hal...

2020-01-09 09:51 3372
Daewoong Infion obtained World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells

Daewoong Pharmaceutical Receives World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells through Indonesian Joint Venture, Daewoong Infion

SEOUL, South Korea, Jan. 8, 2020 /PRNewswire/ -- Daewoong Infion Co. has achieved world's first ha...

2020-01-08 11:00 1378
123